Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide receptor (GLP-1R), which is a G-protein coupled receptor (GPCR), signals through both Gαs and Gαq coupled pathways and ERK phosphorylation to stimulate insulin secretion. The aim of this study was to determine molecular details of the effect of small molecule agonists, compounds 2 and B, on GLP-1R mediated cAMP production, intracellular Ca2+ accumulation, ERK phosphorylation and its internalisation. In human GLP-1R (hGLP-1R) expressing cells, compounds 2 and B induced cAMP production but caused no intracellular Ca2+ accumulation, ERK phosphorylation or hGLP-1R internalisation. GLP-1 antagonists Ex(9-39) and JANT-4 and the orthosteric binding site mutation (V36A) in hGLP-1R failed to inhibit compounds 2 and B induced cAMP production, confirming that their binding site distinct from the GLP-1 binding site on GLP-1R. However, K334A mutation of hGLP-1R, which affects Gαs coupling, inhibited GLP-1 as well as compounds 2 and B induced cAMP production, indicating that GLP-1, compounds 2 and B binding induce similar conformational changes in the GLP-1R for Gαs coupling. Additionally, compound 2 or B binding to the hGLP-1R had significantly reduced GLP-1 induced intracellular Ca2+ accumulation, ERK phosphorylation and hGLP-1R internalisation. This study illustrates pharmacology of differential activation of GLP-1R by GLP-1 and compounds 2 and B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Since the GLP-1 receptor (GLP-1R) agonists are effective in treating diabesity, they could be pharmacological alternatives to bariatric surgery but without the post-surgery complications.3,13,14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The K334A mutation (which affects the Gαs coupling) of GLP-1R inhibited both GLP-1 and compounds 2 and B induced cAMP production, which demonstrates that GLP-1 and both compounds 2 and B induce similar conformational changes needed for the Gαs activation.14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Compounds 2 and B induced cAMP production in human GLP-1R expressing cells but caused no intracellular Ca2+ accumulation, ERK phosphorylation or receptor internalisation.14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
In the citing paper
“Compounds A and B have also been shown to demonstrate ago-allosteric properties and induce cyclic adenosine monophosphate (cAMP) signalling, as well as increased insulin secretion in rat islets and animal studies.3,14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
In the citing paper
“Compounds 2 and B bind to a distinct site from the orthosteric binding site, as GLP-1R antagonists exendin (9–39) and JANT4, as well as the V36A mutation in GLP-1R, did not inhibit cAMP production upon compound 2 or B administration.14”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“The agonist occupied GLP-1R signals through both the Gαs and Gαq coupled pathways [3, 5, 6].”
BackgroundGöke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 5×
“Ex(9–39) and JANT-4 are known antagonist of the GLP-1R that work by binding to the orthosteric binding site [9, 10, 26, 32], which therefore competitively inhibit GLP-1 binding to the receptor.”
BackgroundInfluentialMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Regulation of GPCRs by Endocytic Membrane Trafficking and Its Potential Implications
Hanyaloglu, A. C., & Zastrow, M. V. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094830 · Cited by 609 · cited 1×
“Reducing hGLP-1R internalisation prevents dampening of the receptor activity [43].”
BackgroundThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Allosteric Modulation of the Cannabinoid CB1 Receptor
Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 443 · cited 1×
“This result is similar to the effect of allosteric agonists of the cannabinoid CB1 receptor, because their binding to the receptor results in a conformation change that increases the affinity of the orthosteric agonist to the receptor [46].”
BackgroundØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295 · cited 2×
“The V36A mutation in the GLP-1R has previously been shown to affect GLP-1 binding to the orthosteric binding site [35].”
BackgroundMa, L., Seager, M. A., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900903106 · Cited by 285 · cited 1×
“Additionally, the allosteric agonist AC-42 binds to the M1 muscarinic acetylcholine receptor, which results in ERK phosphorylation and intracellular Ca mobilisation but not internalisation of the receptor [41, 42].”
BackgroundSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 9×
“However, compounds 2 and B not only induce insulin secretion but also inhibit GLP-1R internalisation [17, 18, 20], indicating that GLP-1R may use multiple and compensatory pathways to induce insulin secretion in pancreatic islets.”
BackgroundResultInfluential
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Self-citationTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
Conserved class B GPCR activation by a biased intracellular agonist
Zhao, L., He, Q., Yuan, Q., Gu, Y., He, X., Shan, H., Li, J., Wang, K., Li, Y., Hu, W., et al. (2023) · Nature · doi:10.1038/s41586-023-06467-w · Cited by 67
Treatment of type 2 diabetes: future approaches
Bailey, C. J., & Day, C. (2018) · British Medical Bulletin · doi:10.1093/brimed/ldy013 · Cited by 61
“This modifies the conformation and signalling activity of the GLP-1 receptors, offering the potential to increase receptor binding of endogenous GLP-1 or exogenous peptide GLP-1 receptor agonists.(26) Whether the profile of metabolic and other effects generated in this way will exactly replicate native GLP-1 remains t…”
BackgroundRho kinase-dependent desensitization of GPR39; a unique mechanism of GPCR downregulation
Shimizu, Y., Koyama, R., & Kawamoto, T. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.115 · Cited by 28
“For example, phosphorylated extracellular signal-regulated kinase (ERK) mediated by Gq-pathway activation reportedly is important for GLP-1R internalization [20,21].”
BackgroundExendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus
Sharma, P., Singh, S., Thakur, V., Sharma, N., & Grewal, A. S. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100329 · Cited by 33
Liu, N., Cui, X. Y., Yan, W., Guo, T., Wang, Z., Wei, X., Sun, Y., Liu, J., Cheng, X., Ma, W., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100968 · Cited by 26
“The further re-searches revealed that non-peptide ligands, for example 4-(3-(Benzyloxy)phenyl)-2-(ethylsul fi nyl)-6-(tri fl uoromethyl)pyrimidine (BETP) [19], compound 2 and B [20] and LY3502970 [17] can activate GLP-1R and perform the similar effects like GLP-1 analogues.”
BackgroundModulation of Diabetes by Natural Products and Medicinal Plants via Incretins
Ríos, J.-L., Andújar, I., Schinella, G. R., & Francini, F. (2019) · Planta Medica · doi:10.1055/a-0897-7492 · Cited by 21
“Recently, studies have focused on identifying non-peptidic agonists for the GLP-1 receptor [46,47].”
BackgroundGermano, J. D. F., Huang, C., Sin, J., Song, Y., Tucker, K. C., Taylor, D. J. R., Saadaeijahromi, H., Stotland, A. B., Piplani, H., Gottlieb, R. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64924-2 · Cited by 21
Molecular study of the proliferation process of beta cells derived from pluripotent stem cells
Akhavan, S., Tutunchi, S., Malmir, A., Ajorlou, P., Jalili, A., & Panahi, G. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06892-y · Cited by 13
“1 3 by binding to GLP-1R, increase cAMP and intracellular Ca2+ production and ERK phosphorylation, all of which lead to beta cells proliferation [48].”
BackgroundJannoo, R., Walker, W., & Kanamarlapudi, V. (2023) · Cancers · doi:10.3390/cancers15102772 · Cited by 7
“…cells were transfected for 48 h with expression plasmid IL-13R α 2-mCherry [11] or Myc-LHCGR [34] or an empty control plasmid (mCherry) using jetPRIME ® transfection reagent (Polyplus-transfection SA (#101000015), Illkirch-Graffenstaden, France) according to the manufacturer’s instructions [35].”
MethodSelf-citationReed, J., Higginbotham, V., Bain, S. C., & Kanamarlapudi, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126331 · Cited by 3
“However, the agonists were able to boost cAMP production at 2.5 mM glucose, but not to the same extent as what was observed for the 15 mM glucose exposure.”
BackgroundMethodInfluentialSelf-citationResearch advances in understanding crosstalk between organs and pancreatic β‐cell dysfunction
Huang, P., Zhu, Y., & Qin, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15787 · Cited by 3
“97,98 The synthesis of cAMP then stimulates protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), facilitating insulin granule release by priming insulin granules.”
Molecular characterisation of small molecule agonists and internalisation of GLP‐1R
Kanamarlapudi, V. (2018) · The FASEB Journal · doi:10.1096/fasebj.2018.32.1_supplement.670.57
Self-citationReed, J., & Kanamarlapudi, V. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101967-1
Self-citationReed, J., & Kanamarlapudi, V. (2018) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101967-2
Self-citationZhao, L., He, Q., Yuan, Q., Gu, Y., He, X., Li, J., Wang, K., Li, Y., Shen, J., & Xu, H. E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.08.544171
Metadata
- Authors
- Thompson, A., Stephens, J. W., Bain, S. C., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Kanamarlapudi, Venkateswarlu
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-04-21
- Volume
- 11
- Issue
- 4
- Pages
- e0154229
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4839733
- OpenAlex
- W2341529564
- Cited by
- 19
- References
- 48
- Citations by year
- 2024: 3 · 2023: 3 · 2021: 6 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Biotechnology and Biological Sciences Research Council (BB/F017596/1, BB/C515455/2)
- Medical Research Council (G0401232)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, GLP-1 receptor agonists, receptor internalization, G protein-coupled receptor signaling, cAMP production, intracellular calcium accumulation, ERK1/2 phosphorylation, orthosteric binding site, receptor conformational change, small molecule agonists
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Cyclic AMP, Binding Sites, Calcium, Endocytosis, Humans, Mutation, Peptide Fragments, Peptides, Phosphorylation, Venoms, Immunoblotting, Signal Transduction, Microscopy, Confocal, Intracellular Space, Extracellular Signal-Regulated MAP Kinases, Glucagon-Like Peptide 1, Small Molecule Libraries, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.